Kura Oncology (NASDAQ:KURA) Raised to “Buy” at StockNews.com

Kura Oncology (NASDAQ:KURA) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday.

KURA has been the subject of several other reports. UBS Group decreased their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. JMP Securities reissued a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Thursday, February 27th. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.50.

Kura Oncology Trading Down 4.5 %

NASDAQ KURA opened at $5.89 on Friday. The firm has a market cap of $475.65 million, a PE ratio of -2.50 and a beta of 0.83. Kura Oncology has a 52 week low of $5.82 and a 52 week high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average price of $7.68 and a 200 day moving average price of $11.51.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, sell-side analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Kura Oncology by 7.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after acquiring an additional 9,050 shares during the last quarter. Woodline Partners LP lifted its holdings in Kura Oncology by 20.6% in the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock valued at $1,504,000 after acquiring an additional 29,497 shares during the last quarter. Velan Capital Investment Management LP purchased a new position in Kura Oncology in the fourth quarter worth approximately $1,306,000. Squarepoint Ops LLC acquired a new stake in Kura Oncology during the fourth quarter worth $799,000. Finally, Two Sigma Advisers LP raised its position in Kura Oncology by 147.1% in the fourth quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock valued at $2,110,000 after purchasing an additional 144,201 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.